Mu Opioid Receptor Modulation of Dopamine Neurons in the Periaqueductal Gray/Dorsal Raphe: A Role in Regulation of Pain

Neuropsychopharmacology

Volumn 41, Issue 8, 2016, Pages 2122-2132

  Li, Chia ^a,b   Sugam, Jonathan A ^b   Lowery Gionta, Emily G ^b   McElligott, Zoe A ^b   McCall, Nora M ^b   Lopez, Alberto J ^b   McKlveen, Jessica M ^b   Pleil, Kristen E ^b   Kash, Thomas L ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIGNER DRUG; GLUTAMIC ACID; GREEN FLUORESCENT PROTEIN; MU OPIATE RECEPTOR; TYROSINE 3 MONOOXYGENASE; DOPAMINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE];

ADULT; ANIMAL CELL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; ELECTROPHYSIOLOGY; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MALE; MOUSE; NEUROANATOMY; NEUROCHEMISTRY; NOCICEPTION; NONHUMAN; OPTOGENETICS; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; AGONISTS; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; INHIBITORY POSTSYNAPTIC POTENTIAL; METABOLISM; PHYSIOLOGY; SEPTUM NUCLEUS; TRANSGENIC MOUSE;

ANIMALS; DOPAMINE; DOPAMINERGIC NEURONS; DORSAL RAPHE NUCLEUS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GLUTAMIC ACID; INHIBITORY POSTSYNAPTIC POTENTIALS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PAIN PERCEPTION; PERIAQUEDUCTAL GRAY; RECEPTORS, OPIOID, MU; SEPTAL NUCLEI; TYROSINE 3-MONOOXYGENASE;

EID: 84973641595     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.12     Document Type: Article

References (40)

1. Akaike A, Shibata T, Satoh M, Takagi H (1978). Analgesia induced by microinjection of morphine into, and electrical stimulation of, the nucleus reticularis paragigantocellularis of rat medulla oblongata. Neuropharmacology 17: 775-778.
2. Bath BD, Michael DJ, Trafton BJ, Joseph JD, Runnels PL, Wightman RM (2000). Subsecond adsorption and desorption of dopamine at carbon-fiber microelectrodes. Anal Chem 72: 5994-6002.
3. Beiske AG, Loge JH, Ronningen A, Svensson E (2009). Pain in Parkinson's disease: prevalence and characteristics. Pain 141: 173-177.
4. Bergevin A, Girardot D, Bourque MJ, Trudeau LE (2002). Presynaptic mu-opioid receptors regulate a late step of the secretory process in rat ventral tegmental area GABAergic neurons. Neuropharmacology 42: 1065-1078.
5. Budai D, Fields HL (1998). Endogenous opioid peptides acting at mu-opioid receptors in the dorsal horn contribute to midbrain modulation of spinal nociceptive neurons. J Neurophysiol 79: 677-687.
6. Crown ED, King TE, Meagher MW, Grau JW (2000). Shockinduced hyperalgesia: III. Role of the bed nucleus of the stria terminalis and amygdaloid nuclei. Behav Neurosci 114: 561-573.
7. Deyama S, Nakagawa T, Kaneko S, Uehara T, Minami M (2007). Involvement of the bed nucleus of the stria terminalis in the negative affective component of visceral and somatic pain in rats. Behav Brain Res 176: 367-371.
8. Dougalis AG, Matthews GA, Bishop MW, Brischoux F, Kobayashi K, Ungless MA (2012). Functional properties of dopamine neurons and co-expression of vasoactive intestinal polypeptide in the dorsal raphe nucleus and ventro-lateral periaqueductal grey. Eur J Neurosci 36: 3322-3332.
9. Espejo EF, Stinus L, Cador M, Mir D (1994). Effects of morphine and naloxone on behaviour in the hot plate test: an ethopharmacological study in the rat. Psychopharmacology 113: 500-510.
10. Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA et al (2003). Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45: 594-604.
11. Flores JA, El Banoua F, Galan-Rodriguez B, Fernandez-Espejo E (2004). Opiate anti-nociception is attenuated following lesion of large dopamine neurons of the periaqueductal grey: critical role for D1 (not D2) dopamine receptors. Pain 110: 205-214.
12. Franklin KJ, Abbott F (1989). Techniques for assessing the effects of drugs on nociceptive responses. In: Boulton A et al (ed). Psychopharmacology, Vol. 13, Humana Press: Clifton, NJ, pp 145-216.
13. Hahm ET, Kim Y, Lee JJ, Cho YW (2011). GABAergic synaptic response and its opioidergic modulation in periaqueductal gray neurons of rats with neuropathic pain. BMC Neurosci 12: 41.
14. Heimer R, Zhan W, Grau LE (2015). Prevalence and experience of chronic pain in suburban drug injectors. Drug Alcohol Depend 151: 92-100.
15. Hnasko TS, Chuhma N, Zhang H, Goh GY, Sulzer D, Palmiter RD et al (2010). Vesicular glutamate transport promotes dopamine storage and glutamate corelease in vivo. Neuron 65: 643-656.
16. Hong J, Novick D, Montgomery W, Aguado J, Duenas H, Peng X et al (2015). Should unexplained painful physical symptoms be considered within the spectrum of depressive symptoms? Clin Pract Epidemiol Ment Health 11: 130-139.
17. Jarcho JM, Mayer EA, Jiang ZK, Feier NA, London ED (2012). Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction. Pain 153: 744-754.
18. Johnson SW, North RA (1992). Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12: 483-488.
19. Kash TL, Nobis WP, Matthews RT, Winder DG (2008). Dopamine enhances fast excitatory synaptic transmission in the extended amygdala by a CRF-R1-dependent process. J Neurosci 28: 13856-13865.
20. Kim EJ, Horovitz O, Pellman BA, Tan LM, Li Q, Richter-Levin G et al (2013a). Dorsal periaqueductal gray-amygdala pathway conveys both innate and learned fear responses in rats. Proc Natl Acad Sci USA 110: 14795-14800.
21. Kim SY, Adhikari A, Lee SY, Marshel JH, Kim CK, Mallory CS et al (2013b). Diverging neural pathways assemble a behavioural state from separable features in anxiety. Nature 496: 219-223.
22. Lecca S, Melis M, Luchicchi A, Muntoni AL, Pistis M (2012). Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse. Neuropsychopharmacology 37: 1164-1176.
23. Li C, McCall NM, Lopez AJ, Kash TL (2013). Alcohol effects on synaptic transmission in periaqueductal gray dopamine neurons. Alcohol 47: 279-287.
24. Lupica CR (1995). Delta and mu enkephalins inhibit spontaneous GABA-mediated IPSCs via a cyclic AMP-independent mechanism in the rat hippocampus. J Neurosci 15: 737-749.
25. Margolis EB, Hjelmstad GO, Fujita W, Fields HL (2014). Direct bidirectional mu-opioid control of midbrain dopamine neurons. J Neurosci 34: 14707-14716.
26. Mayer DJ, Wolfle TL, Akil H, Carder B, Liebeskind JC (1971). Analgesia from electrical stimulation in the brainstem of the rat. Science 174: 1351-1354.
27. Minami M, Ide S (2015). How does pain induce negative emotion? Role of the bed nucleus of the stria terminalis in pain-induced place aversion. Curr Mol Med 15: 184-190.
28. Morano TJ, Bailey NJ, Cahill CM, Dumont EC (2008). Nuclei-and condition-specific responses to pain in the bed nucleus of the stria terminalis. Prog Neuropsychopharmacol Biol Psychiatry 32: 643-650.
29. Rizvi TA, Ennis M, Behbehani MM, Shipley MT (1991). Connections between the central nucleus of the amygdala and the midbrain periaqueductal gray: topography and reciprocity. J Comp Neurol 303: 121-131.
30. Silberman Y, Winder DG (2013). Corticotropin releasing factor and catecholamines enhance glutamatergic neurotransmission in the lateral subdivision of the central amygdala. Neuropharmacology 70: 316-323.
31. Stuber GD, Hnasko TS, Britt JP, Edwards RH, Bonci A (2010). Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate. J Neurosci 30: 8229-8233.
32. Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM et al (2010). Neural bases for addictive properties of benzodiazepines. Nature 463: 769-774.
33. Tecuapetla F, Patel JC, Xenias H, English D, Tadros I, Shah F et al (2010). Glutamatergic signaling by mesolimbic dopamine neurons in the nucleus accumbens. J Neurosci 30: 7105-7110.
34. Tritsch NX, Ding JB, Sabatini BL (2012). Dopaminergic neurons inhibit striatal output through non-canonical release of GABA. Nature 490: 262-266.
35. Tykocki T, Kornakiewicz A, Mandat T, Nauman P (2013). Pain perception in patients with Parkinson's disease. J Clin Neurosci 20: 663-666.
36. Vaughan CW, Ingram SL, Connor MA, Christie MJ (1997). How opioids inhibit GABA-mediated neurotransmission. Nature 390: 611-614.
37. Vianna DM, Brandao ML (2003). Anatomical connections of the periaqueductal gray: specific neural substrates for different kinds of fear. Braz J Med Biol Res 36: 557-566.
38. Weaver M, Schnoll S (2002). Abuse liability in opioid therapy for pain treatment in patients with an addiction history. Clin J Pain 18: S61-S69.
39. Wood PB (2008). Role of central dopamine in pain and analgesia. Expert Rev Neurother 8: 781-797.
40. Xie G, Hipolito L, Zuo W, Polache A, Granero L, Krnjevic K et al (2012). Salsolinol stimulates dopamine neurons in slices of posterior ventral tegmental area indirectly by activating mu-opioid receptors. J Pharmacol Exp Ther 341: 43-50.